UY40678A - Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación - Google Patents

Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación

Info

Publication number
UY40678A
UY40678A UY0001040678A UY40678A UY40678A UY 40678 A UY40678 A UY 40678A UY 0001040678 A UY0001040678 A UY 0001040678A UY 40678 A UY40678 A UY 40678A UY 40678 A UY40678 A UY 40678A
Authority
UY
Uruguay
Prior art keywords
manufacture
methods
fusion proteins
present
vaccine formulations
Prior art date
Application number
UY0001040678A
Other languages
English (en)
Spanish (es)
Inventor
Sambhaji Shankar Pisal
Dattatreya Sarma Annamraju
Rajeev Mhalasakant Dhere
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of UY40678A publication Critical patent/UY40678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
UY0001040678A 2023-03-24 2024-03-22 Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación UY40678A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (https=) 2023-03-24 2023-03-24

Publications (1)

Publication Number Publication Date
UY40678A true UY40678A (es) 2024-10-15

Family

ID=92903953

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001040678A UY40678A (es) 2023-03-24 2024-03-22 Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación

Country Status (12)

Country Link
EP (1) EP4687967A1 (https=)
JP (1) JP2026511179A (https=)
KR (1) KR20250166279A (https=)
CN (1) CN121038809A (https=)
AR (1) AR132199A1 (https=)
AU (1) AU2024249503A1 (https=)
IL (1) IL323559A (https=)
IN (1) IN202321021121A (https=)
MX (1) MX2025011286A (https=)
TW (1) TW202444740A (https=)
UY (1) UY40678A (https=)
WO (1) WO2024201502A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025224732A1 (en) * 2024-04-26 2025-10-30 Techinvention Lifecare Private Limited Meningococcal hexavalent combination vaccine
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110804102B (zh) * 2019-11-08 2021-07-20 苏州微超生物科技有限公司 B群脑膜炎球菌疫苗及其制备方法与应用

Also Published As

Publication number Publication date
AR132199A1 (es) 2025-06-04
JP2026511179A (ja) 2026-04-10
MX2025011286A (es) 2025-11-03
CN121038809A (zh) 2025-11-28
KR20250166279A (ko) 2025-11-27
WO2024201502A1 (en) 2024-10-03
TW202444740A (zh) 2024-11-16
IN202321021121A (https=) 2024-04-19
IL323559A (en) 2025-11-01
AU2024249503A1 (en) 2025-10-16
EP4687967A1 (en) 2026-02-11

Similar Documents

Publication Publication Date Title
UY40678A (es) Formulaciones de vacunas a base de proteínas meningocócicas y métodos para su fabricación
WO2021154812A8 (en) Coronavirus vaccine formulations
WO2007024941A3 (en) Polyvalent vaccine
AR090294A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
IN2014DN08830A (https=)
WO2010019262A3 (en) Polyvalent vaccine
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
AR082952A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
AR078247A1 (es) Vacuna de pcsk9
AR053833A1 (es) Composicion inmunogenetica
BR112019014397A2 (pt) Composições de neisseria meningitidis e métodos das mesmas
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
CR10559A (es) Vacuna de influenza
CR10123A (es) Vacuna.
WO2023102448A3 (en) Coronavirus vaccine formulations
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
MX2022015734A (es) Proteinas de exotoxina a modificadas.
MX2023011163A (es) Formulaciones para vacuna contra coronavirus.
DK1765289T3 (da) Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
HK1198137A1 (en) Disinfecting formulations and uses thereof
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
DOP2024000016A (es) Proteínas actrii y usos de las mismas
NO20071636L (no) Flytende allergivaksineformulering for oromukosal administrering
AR117191A1 (es) Composiciones inmunogénicas